Physician profile
Sayed Osama
NPI 1467442038
$3,089.16
in general payments reported to CMS, 2019-2025
27 companies · $925 in 2025
The $925 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $188 · 2021: $280 · 2022: $200 · 2023: $416 · 2024: $848 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.08 |
| Education | $177.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $279.46 | 2019-2025 | Farxiga |
| Amgen INC. | $259.24 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $231.89 | 2020-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $226.77 | 2019-2022 | |
| Akebia Therapeutics INC | $225.38 | 2020-2025 | Vafseo |
| Travere Therapeutics, INC. | $194.25 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $193.50 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.02 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $166.61 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $148.69 | 2023-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $132.99 | 2021-2024 | Nxstage System One, Crit-Line |
| Recor Medical INC | $121.15 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Scpharmaceuticals INC. | $119.05 | 2024-2025 | |
| Horizon Therapeutics Plc | $105.12 | 2021-2023 | Krystexxa |
| Genzyme Corporation | $100.83 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $90.08 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $56.05 | 2023-2025 | |
| Cormedix INC. | $45.71 | 2024-2025 | Defencath, Defencath |
| Glaxosmithkline, LLC. | $42.90 | 2021-2023 | Benlysta |
| Novo Nordisk INC | $42.41 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $34.12 | 2024 | Mounjaro, Zepbound |
| Chiesi USA, INC. | $25.30 | 2025 | Elfabrio |
| Mallinckrodt Enterprises LLC | $23.34 | 2019 | |
| Ardelyx, INC. | $21.94 | 2023 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $18.14 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2025 | Gattex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Osama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.